Emergent BioSolutions Inc. (EBS)

Market Cap	376.15M
Revenue (ttm)	965.40M
Net Income (ttm)	-131.60M
Shares Out	54.28M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	11.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	867,717
Open	7.34
Previous Close	7.30
Day's Range	6.88 - 7.36
52-Week Range	4.02 - 15.10
Beta	2.09
Analysts	Strong Buy
Price Target	14.33 (+106.78%)
Earnings Date	Aug 6, 2025

About EBS

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 15, 2006
• Employees: 900
• Stock Exchange: NYSE
• Ticker Symbol: EBS
• Website: https://www.emergentbiosolutions.com

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for EBS stock is "Strong Buy." The 12-month stock price target is $14.33, which is an increase of 106.78% from the latest price.

Price Target

$14.33

(106.78% upside)

Analyst Consensus: Strong Buy